

Refine Search

Search Results -

Term	Documents
(19 NOT 20).PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD.	63
(L19 NOT L20).PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD.	63

Database:

US Pre-Grant Publication Full-Text Database
 US Patents Full-Text Database
 US OCR Full-Text Database
 EPO Abstracts Database
 JPO Abstracts Database
 Derwent World Patents Index
 IBM Technical Disclosure Bulletins

Search:

Refine Search

Recall Text

Clear

Interrupt

Search History

DATE: Tuesday, October 26, 2004 [Printable Copy](#) [Create Case](#)

<u>Set</u> <u>Name</u>	<u>Query</u>	<u>Hit</u> <u>Count</u>	<u>Set</u> <u>Name</u> result set
side by side			
DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD; THES=ASSIGNEE; PLUR=YES; OP=AND			
<u>L21</u>	L19 not L20	63	<u>L21</u>
<u>L20</u>	L19 and L17	8	<u>L20</u>
<u>L19</u>	L2 same (proliferation)	71	<u>L19</u>
<u>L18</u>	L17 not L11	265	<u>L18</u>
<u>L17</u>	L16 and L14	391	<u>L17</u>
<u>L16</u>	(inhibit or reduce) same (proliferation)	25725	<u>L16</u>
<u>L15</u>	L14 and L6	13	<u>L15</u>
<u>L14</u>	L13 and L3	555	<u>L14</u>
<u>L13</u>	L12 and L2	1348	<u>L13</u>
<u>L12</u>	(screening or testing or identifying) same (drug or inhibitor or agent)	109604	<u>L12</u>
<u>L11</u>	L10 and (induced adj proliferation)	127	<u>L11</u>

<u>L10</u>	L2 and (pravastatin or atorvastatin or simvastatin or lovastatin or pindolol or meththiotepin or metoprolol or paldolol)	344	<u>L10</u>
<u>L9</u>	L8 not L7	0	<u>L9</u>
<u>L8</u>	L6 and L2	15	<u>L8</u>
<u>L7</u>	L6 and L5	15	<u>L7</u>
<u>L6</u>	(inhibit or inhibitor or drug or agent) same (induced adj proliferation)	614	<u>L6</u>
<u>L5</u>	L4 and L2	2233	<u>L5</u>
<u>L4</u>	(heart adj valve) same (degeneration or thrombosis or calcification or disease)	2233	<u>L4</u>
<u>L3</u>	(heart adj valve) same (degeneration or throbois or calcification or disease)	1972	<u>L3</u>
<u>L2</u>	(heart adj valve) or (valvular adj (tissue or endothelial))	8920	<u>L2</u>
<u>L1</u>	Rajamannan-Nalini-M\$.in.	4	<u>L1</u>

END OF SEARCH HISTORY



Day : Tuesday
Date: 10/26/2004
Time: 14:19:08

Inventor Name Search

Enter the **first few letters** of the Inventor's Last Name.
Additionally, enter the **first few letters** of the Inventor's First name.

Last Name

First Name

To go back use Back button on your browser toolbar.

Back to [PALM](#) | [ASSIGNMENT](#) | [OASIS](#) | [Home page](#)

Welcome to DialogClassic Web(tm)

Dialog level 04.18.01D

Last logoff: 25oct04 09:12:20

Logon file001 26oct04 14:34:51

*** ANNOUNCEMENT ***

--Connect Time joins DialUnits as pricing options on Dialog.
See HELP CONNECT for information.

--SourceOne patents are now delivered to your email inbox
as PDF replacing TIFF delivery. See HELP SOURCE1 for more
information.

--Important Notice to Freelance Authors--
See HELP FREELANCE for more information

NEW FILES RELEASED

***Beilstein Abstracts (File 393)

***Beilstein Facts (File 390)

***Beilstein Reactions (File 391)

***F-D-C Gold/Silver Sheet (File 184)

***BIOSIS Toxicology (File 157)

***IPA Toxicology (File 153)

UPDATING RESUMED

*** RELOADED

***Toxfile (File 156)

REMOVED

***Textile Technology Digest (File 119)

>>> Enter BEGIN HOMEBASE for Dialog Announcements <<<
>>> of new databases, price changes, etc. <<<

KWIC is set to 50.

HILIGHT set on as ' '

* * *

File 1:ERIC 1966-2004/Jul 21

(c) format only 2004 The Dialog Corporation

Set Items Description

--- -----

Cost is in DialUnits

?

B 155, 5, 73

26oct04 14:35:04 User259876 Session D684.1

\$0.73 0.208 DialUnits File1

\$0.73 Estimated cost File1

\$0.05 INTERNET

\$0.78 Estimated cost this search

\$0.78 Estimated total session cost 0.208 DialUnits

SYSTEM:OS - DIALOG OneSearch

File 155:MEDLINE(R) 1951-2004/Oct W4

(c) format only 2004 The Dialog Corp.

File 5:Biosis Previews(R) 1969-2004/Oct W3

(c) 2004 BIOSIS

File 73:EMBASE 1974-2004/Oct W3

(c) 2004 Elsevier Science B.V.

Set Items Description

--- -----

?

S (HEART (W) VALVE) (W) (DEGENERATION OR THROMBOSIS OR CALCIFICATION)
 1845387 HEART
 204442 VALVE
 193224 DEGENERATION
 224910 THROMBOSIS
 63559 CALCIFICATION
 S1 269 (HEART (W) VALVE) (W) (DEGENERATION OR THROMBOSIS OR
 CALCIFICATION)

?

S S1 (S) (INHIBITOR OR DRUG)
 269 S1
 964040 INHIBITOR
 8317261 DRUG
 S2 13 S1 (S) (INHIBITOR OR DRUG)

?

RD
 ...completed examining records
 S3 7 RD (unique items)

?

T S3/3,K/ALL

3/3,K/1 (Item 1 from file: 155)

DIALOG(R) File 155:MEDLINE(R)

(c) format only 2004 The Dialog Corp. All rts. reserv.

12819432 PMID: 7586894

Novel delivery of antiarrhythmic agents.

Labhasetwar V; Levy R J
 University of Michigan Medical Center, Division of Pediatric Cardiology,
 Ann Arbor, USA.

Clinical pharmacokinetics (NEW ZEALAND) Jul 1995, 29 (1) p1-5,

ISSN 0312-5963 Journal Code: 7606849

Contract/Grant No.: HL41663; HL; NHLBI

Document type: Journal Article; Review; Review, Tutorial

Languages: ENGLISH

Main Citation Owner: NLM

Record type: Completed

... compounds, which are otherwise more potent and less toxic than available agents. The regional nature of the several cardiac diseases, such as ischaemia, restenosis or heart valve calcification, may require a high concentration of drug at the location of the disease, which by conventional routes may not be attainable due to systemic toxicity of the drug. Localised cardiac delivery of antiarrhythmic agents, based on drug-polymer implants, may have several advantages, including enhanced drug effects and reduced systemic drug toxicity. Computer-assisted automated feedback systems may further enhance the usefulness of this therapy in the clinical setting. Before clinical application of this method of drug delivery further study will be required, but it is hypothesised that pharmacokinetic variability for drugs delivered in this manner will be reduced and therefore efficacy...

3/3,K/2 (Item 2 from file: 155)

DIALOG(R) File 155:MEDLINE(R)

(c) format only 2004 The Dialog Corp. All rts. reserv.

07972580 PMID: 3144594

Controlled release of diphosphonates from synthetic polymers to inhibit calcification.

Golomb G

Department of Pharmacy, School of Pharmacy, Hebrew University of Jerusalem, Israel.

Journal of biomaterials applications (UNITED STATES) Oct 1987, 2 (2)
 p266-89, ISSN 0885-3282 Journal Code: 8813912

Document type: Journal Article
Languages: ENGLISH
Main Citation Owner: NLM
Record type: Completed

... bioprosthetic heart valves fabricated from glutaraldehyde pretreated porcine aortic valves or bovine pericardium. Formulation and evaluation of controlled-release drug delivery system to inhibit bioprosthetic heart valve calcification is reviewed.

3/3,K/3 (Item 3 from file: 155)

DIALOG(R)File 155:MEDLINE(R)

(c) format only 2004 The Dialog Corp. All rts. reserv.

07567869 PMID: 3116348

Prevention of leaflet calcification of bioprosthetic heart valves with diphosphonate injection therapy. Experimental studies of optimal dosages and therapeutic durations.

Levy R J; Schoen F J; Lund S A; Smith M S
Division of Pediatric Cardiology, C.S. Mott Children's Hospital,
University of Michigan Medical Center, Ann Arbor 48109.
Journal of thoracic and cardiovascular surgery (UNITED STATES) Oct 1987
, 94 (4) p551-7, ISSN 0022-5223 Journal Code: 0376343
Contract/Grant No.: HL32261; HL; NHLBI; HL32346; HL; NHLBI
Document type: Journal Article
Languages: ENGLISH
Main Citation Owner: NLM
Record type: Completed

... received daily subcutaneous injections of the drug (1, 5, 10, 15, or 25 mg/kg/24 hr) for 21 days with maximal inhibition of bioprosthetic heart valve calcification at a dosage of 15 mg/kg/24 hr (calcium level of diphosphonate-treated bioprostheses 3.5 +/- 0.5 micrograms/ml; calcium level of control...

... mg), but with irreversibly diminished bone and somatic growth. A dosage optimum was observed at 10 mg/kg/24 hr with significant inhibition of bioprosthetic heart valve calcification (at 21 days, the calcium level was 16.4 +/- 3.6 micrograms/mg) and an absence of adverse effects on epiphyseal development and overall growth...

... more calcification after 21 days than did bioprostheses from animals treated for 2 or 3 weeks. Bioprostheses explanted after 110 days from animals receiving the drug (15 mg/kg/24 hr) for the first 3 weeks had calcification equivalent to that of untreated control rats. Diphosphonate (15 mg/kg/24 hr...

3/3,K/4 (Item 4 from file: 155)

DIALOG(R)File 155:MEDLINE(R)

(c) format only 2004 The Dialog Corp. All rts. reserv.

07483079 PMID: 3110404

Controlled-release drug delivery of diphosphonates to inhibit bioprosthetic heart valve calcification: release rate modulation with silicone matrices via drug solubility and membrane coating.

Golomb G; Dixon M; Smith M S; Schoen F J; Levy R J
Journal of pharmaceutical sciences (UNITED STATES) Apr 1987, 76 (4)
p271-6, ISSN 0022-3549 Journal Code: 2985195R
Contract/Grant No.: HL32261; HL; NHLBI
Document type: Journal Article
Languages: ENGLISH
Main Citation Owner: NLM
Record type: Completed

Controlled-release drug delivery of diphosphonates to inhibit bioprosthetic heart valve calcification : release rate modulation with silicone matrices via drug solubility and membrane coating.

3/3,K/5 (Item 1 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)

(c) 2004 BIOSIS. All rts. reserv.

0014260707 BIOSIS NO.: 200300219426

Mechanical prosthetic heart valve thrombosis: Fibrinolysis or surgery? A single center study about 253 patients.

AUTHOR: Roudaut R (Reprint); Lafitte S (Reprint); Roudaut M F (Reprint); Jais C (Reprint); Coste P (Reprint); Roques X (Reprint); Deville C (Reprint); Baudet E (Reprint)

AUTHOR ADDRESS: Hopital Cardiologique, Pessac, France**France

JOURNAL: European Heart Journal 23 (Abstract Supplement): p439

August-September 2002 2002

MEDIUM: print

CONFERENCE/MEETING: Congress of the European Society of Cardiology Berlin, Germany August 31-September 04, 2002; 20020831

SPONSOR: European Society of Cardiology

ISSN: 0195-668X (ISSN print)

DOCUMENT TYPE: Meeting; Meeting Abstract

RECORD TYPE: Citation

LANGUAGE: English

DESCRIPTORS:

...DISEASES: heart disease, drug therapy, surgery

3/3,K/6 (Item 2 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)

(c) 2004 BIOSIS. All rts. reserv.

0008253765 BIOSIS NO.: 199293096656

SCANNING ELECTRON MICROSCOPY STUDIES OF THE PREVENTION OF BIOPROSTHETIC HEART VALVE CALCIFICATION WITH CONTROLLED RELEASE POLYMERIC MATRICES

AUTHOR: PATHAK Y V (Reprint); BOYD J; JOHNSTON T P; LEVY J T; GOLOMB G; SCHOEN F J; LEVY R J

AUTHOR ADDRESS: R-5014 KRESGE II, UNIV MICH, ANN ARBOR, MICH 48109-0576, USA**USA

JOURNAL: Cells and Materials 1 (1): p65-72 1991

ISSN: 1051-6794

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: ENGLISH

...ABSTRACT: consisting of either ethanehydroxydiphosphonate, FeCl₃ or Al(NO₃)₃ coimplanted with bioprosthetic tissue prevent experimental bioprosthetic calcification. SEM has also been used to study the drug particle distribution in the controlled release matrices. Furthermore, matrix drug release in vitro and in vivo has also been characterized and quantified using SEM techniques.

3/3,K/7 (Item 3 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)

(c) 2004 BIOSIS. All rts. reserv.

0006962522 BIOSIS NO.: 199039015911

CONTROLLED RELEASE IMPLANTS FOR CARDIOVASCULAR DISEASE

BOOK TITLE: ANDERSON, J. M., S. W. KIM AND K. KNUTSON (ED.). ADVANCES IN DRUG DELIVERY SYSTEMS, VOL. 4; INTERNATIONAL SYMPOSIUM ON RECENT ADVANCES IN DRUG DELIVERY SYSTEMS, SALT LAKE CITY, UTAH, USA, FEBRUARY 21-24,

1989. X+359P. ELSEVIER SCIENCE PUBLISHERS B.V.: AMSTERDAM, NETHERLANDS;
NEW YORK, NEW YORK, USA. ILLUS

AUTHOR: LEVY R J (Reprint); JOHNSTON T P; SINTOV A; GOLOMB G
AUTHOR ADDRESS: DEP PEDIATR, UNIV MICH, R-5014 KRESGE II, 0576, ANN ARBOR,
MICH 48109-0576, USA**USA

SERIES TITLE: Advances in Drug Delivery Systems p245-254 1990

ISBN: 0-444-88225-1

DOCUMENT TYPE: Book; Meeting

RECORD TYPE: Citation

LANGUAGE: ENGLISH

DESCRIPTORS: DOG RAT SHEEP VENTRICULAR TACHYCARDIA PROSTHETIC HEART VALVE
CALCIFICATION ETHANEHYDROXYDIPHOSPHONATE CARDIOVASCULAR- DRUG LIDOCAINE
HYDROCHLORIDE ANTIARRHYTHMIC- DRUG

?

Set	Items	Description
S1	269	(HEART (W) VALVE) (W) (DEGENERATION OR THROMBOSIS OR CALCI- FICATION)
S2	13	S1 (S) (INHIBITOR OR DRUG)
S3	7	RD (unique items)
?		
S S1 (S) (INDUCED W) PROLIFERATION)		
>>>Unmatched parentheses		
?		
S S1 (S) (INDUCED (W) PROLIFERATION)		
	269	S1
	3169280	INDUCED
	522377	PROLIFERATION
S4	0	S1 (S) (INDUCED (W) PROLIFERATION)
?		
S (INHIBITOR OR DRUG OR ANTAGONIST) (S) (PROLIFERATION AND (HEART (W) VALVE))		
	964040	INHIBITOR
	8317261	DRUG
	436570	ANTAGONIST
	522377	PROLIFERATION
	1845387	HEART
	204442	VALVE
	50434	HEART(W) VALVE
S5	12	(INHIBITOR OR DRUG OR ANTAGONIST) (S) (PROLIFERATION AND (HEART (W) VALVE))
?		
RD		
...completed examining records		
	S6	9 RD (unique items)
?		
T S6/3,K/ALL		

6/3,K/1 (Item 1 from file: 155)

DIALOG(R)File 155:MEDLINE(R)

(c) format only 2004 The Dialog Corp. All rts. reserv.

16932921 PMID: 15212624

Sarpogrelate: cardiovascular and renal clinical potential.

Doggrell Sheila A

Doggrell Biomedical Communications, 47 Caronia Crescent, Lynfield,
Auckland, New Zealand. s.doggrell@extra.co.nz

Expert opinion on investigational drugs (England) Jul 2004, 13 (7)
p865-74, ISSN 1744-7658 Journal Code: 9434197

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: In Process

Sarpogrelate is a selective 5-hydroxytryptamine receptor subtype 2A

(5-HT2A) **antagonist**. It is metabolised to racemic M-1 and both enantiomers of M-1 are also antagonists of 5-HT2A receptors. Sarpogrelate inhibits responses to 5-HT mediated by 5-HT2A receptors such as platelet aggregation, vasoconstriction and vascular smooth muscle **proliferation**. There is no information available on the pharmacokinetics of sarpogrelate. Sarpogrelate is efficacious in animal models of thrombosis, coronary artery spasm, atherosclerosis, restenosis, peripheral vascular...
... disease, myocardial infarction, diabetes and kidney disease. Small clinical trials indicate that sarpogrelate may be beneficial in the treatment of coronary artery disease, angina, restenosis, **heart valve** prostheses surgery, diabetes mellitus, Raynaud's phenomenon, systemic sclerosis and Buerger's disease. Larger, randomised, double-blind, placebo-controlled clinical trials of sarpogrelate in intermittent...

6/3,K/2 (Item 2 from file: 155)

DIALOG(R) File 155:MEDLINE(R)

(c) format only 2004 The Dialog Corp. All rts. reserv.

14439580 PMID: 10433819

Diminished matrix metalloproteinase 2 (MMP-2) in ectomesenchyme-derived tissues of the Patch mutant mouse: regulation of MMP-2 by PDGF and effects on mesenchymal cell migration.

Robbins J R; McGuire P G; Wehrle-Haller B; Rogers S L

Department of Cell Biology and Physiology, University of New Mexico School of Medicine, 149 Basic Medical Sciences Building, Albuquerque, New Mexico, 87131, USA.

Developmental biology (UNITED STATES) Aug 15 1999, 212 (2) p255-63, ISSN 0012-1606 Journal Code: 0372762

Contract/Grant No.: T32HL07736; HL; NHLBI

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: Completed

... significantly less. In addition, the migratory ability of branchial arch cells from normal explants could be reduced in a similar manner using a specific MMP **inhibitor**. Although it is still unclear whether the MMP-2 reduction is a direct result of the absence of response of Ph/Ph cells to PDGF...

6/3,K/3 (Item 3 from file: 155)

DIALOG(R) File 155:MEDLINE(R)

(c) format only 2004 The Dialog Corp. All rts. reserv.

11472750 PMID: 11581595

Operation for anorexigen-associated valvular heart disease.

Caccitolo J A; Connolly H M; Rubenson D S; Orszulak T A; Schaff H V

Division of Cardiovascular Surgery and Cardiovascular Diseases, Mayo Clinic, Rochester, MN 55905, USA.

Journal of thoracic and cardiovascular surgery (United States) Oct 2001, 122 (4) p656-64, ISSN 0022-5223 Journal Code: 0376343

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: Completed

... valve replacement, 5 with concomitant aortic valve replacement. Excised valves demonstrated a glistening white appearance with plaque-like encasement of leaflets and chordae. Focal surface **proliferation** and fibrosis with a "stuck-on" appearance was consistently found. **CONCLUSIONS:** Anorexigen use may lead to severe multivalvular regurgitation with characteristic echocardiographic and pathologic findings. Recognition of **drug**-induced valvulopathy is important because of widespread use of these

medications and the uncertain natural history of the disease. Early surgical experience suggests that valve...

6/3,K/4 (Item 4 from file: 155)

DIALOG(R) File 155:MEDLINE(R)

(c) format only 2004 The Dialog Corp. All rts. reserv.

07035736 PMID: 4090558

[Rational hematologic diagnosis with reference to modern laboratory procedures]

Rationale hamatologische Diagnostik unter Berucksichtigung moderner Laboratoriumsverfahren.

Stobbe H

Zeitschrift fur die gesamte innere Medizin und ihre Grenzgebiete (GERMANY, EAST) Nov 15 1985, 40 (22) p658-60, ISSN 0044-2542

Journal Code: 21730470R

Document type: Journal Article ; English Abstract

Languages: GERMAN

Main Citation Owner: NLM

Record type: Completed

The spectre of methods for the diagnostics and differentiation of haemolytic anaemias, particularly for the establishment of congenital, autoimmune haemolytic, **drug**-conditioned and other anaemias is treated. The clear delimitation of an iron deficiency from a disturbance of the iron distribution is advantageously to be achieved...

... haematopoietic stem cells are particularly evident in the aplastic syndrome of the bone marrow and further haematological diseases concerning the establishment of the intensiveness of **proliferation**. The classification of the acute leukemias demands conventional as well as cytochemical staining methods; recently, it is essentially improved using monoclonal antibodies. In leukemias cytogenetic...

6/3,K/5 (Item 5 from file: 155)

DIALOG(R) File 155:MEDLINE(R)

(c) format only 2004 The Dialog Corp. All rts. reserv.

06804443 PMID: 3922293

Influence of the developmental state of valvular lesions on the antimicrobial activity of cefotaxime in experimental enterococcal infections.

Sullam P M; Drake T A; Tauber M G; Hackbarth C J; Sande M A

Antimicrobial agents and chemotherapy (UNITED STATES) Mar 1985, 27 (3) p320-3, ISSN 0066-4804 Journal Code: 0315061

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: Completed

Descriptors: Cefotaxime--therapeutic use--TU; *Endocarditis, Bacterial --drug therapy--DT; *Heart Valve Diseases-- **drug** therapy--DT; *Streptococcal Infections--drug therapy--DT

6/3,K/6 (Item 1 from file: 73)

DIALOG(R) File 73:EMBASE

(c) 2004 Elsevier Science B.V. All rts. reserv.

12166070 EMBASE No: 2003270282

NFATc1 mediates vascular endothelial growth factor-induced proliferation of human pulmonary valve endothelial cells

Johnson E.N.; Lee Y.M.; Sander T.L.; Rabkin E.; Schoen F.J.; Kaushal S.;

Bischoff J.

J. Bischoff, Dept. of Surgery, Children's Hospital, 300 Longwood Ave.,
Boston, MA 02115 United States
AUTHOR EMAIL: joyce.bischoff@tch.harvard.edu
Journal of Biological Chemistry (J. BIOL. CHEM.) (United States) 17
JAN 2003, 278/3 (1686-1692)
CODEN: JBCHA ISSN: 0021-9258
DOCUMENT TYPE: Journal ; Article
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH
NUMBER OF REFERENCES: 36

...endothelial growth factor (VEGF) signaling through VEGF receptor 2.
VEGF-induced NFATc1 nuclear translocation was inhibited by either
cyclosporin A or a calcineurin-specific peptide **inhibitor** ; these findings
suggest that VEGF stimulates NFATc1 nuclear import in human pulmonary valve
endothelial cells by a calcineurin-dependent mechanism. Importantly, both
cyclosporin A and the calcineurin-specific peptide **inhibitor** reduced
VEGF-induced human pulmonary valve endothelial cell **proliferation** ,
indicating a functional role for NFATc1 in endothelial growth. In contrast,
VEGF-induced **proliferation** of human dermal microvascular and human
umbilical vein endothelial cells was not sensitive to cyclosporin A.
Finally, NFATc1 was detected in the endothelium of human...

...valve leaflets by immunohistochemistry. These results suggest
VEGF-induced NFATc1 activation may be an important mechanism in cardiac
valve maintenance and function by enhancing endothelial **proliferation** .

6/3,K/7 (Item 2 from file: 73)

DIALOG(R)File 73:EMBASE

(c) 2004 Elsevier Science B.V. All rts. reserv.

11742403 EMBASE No: 2002318036

Future potential indications for an oral thrombin inhibitor

ZUKUNFTIGES INDIKATIONSPOTENZIAL EINES ORALEN THROMBININHIBITORS

Haas S.

Dr. S. Haas, Inst. Exp. Onkol./Therapieforschung, Technische Universitat
Munchen, Ismaninger Str. 22, 81675 Munchen Germany

AUTHOR EMAIL: sylvia.haas@lrz.tum.de

Hamostaseologie (HAMOSTASEOLOGIE) (Germany) 2002, 22/3 (118-125)

CODEN: HAEMD ISSN: 0720-9355

DOCUMENT TYPE: Journal ; Review

LANGUAGE: GERMAN SUMMARY LANGUAGE: ENGLISH; GERMAN

NUMBER OF REFERENCES: 35

...with food ingredients and drugs. The search for new antithrombotics
with an improved safety/efficacy profile led to the development of the
direct oral thrombin- **inhibitor** ximelagatran. It can be administered
without routine monitoring of coagulation parameters and does not possess
any of the previously mentioned limitations. The results from clinical...

...as an alternative anticoagulant in heparin induced thrombocytopenia and
for prevention of thromboembolic complications in oncology. Because of the
mitogenic effects of thrombin on the **proliferation** of tumour cells,
additional experimental studies aiming at a potential inhibition of
thrombin-triggered oncogenesis is of uttermost interest.

6/3,K/8 (Item 3 from file: 73)

DIALOG(R)File 73:EMBASE

(c) 2004 Elsevier Science B.V. All rts. reserv.

11419458 EMBASE No: 2001432739

**Cell proliferation in carcinoid valve disease: A mechanism for serotonin
effects**

Rajamannan N.M.; Caplice N.; Anthikad F.; Sebo T.J.; Orszulak T.A.;
 Edwards W.D.; Tajik J.; Schwartz R.S.
 Dr. N.M. Rajamannan, Northwestern University Medical Sch., Division of
 Cardiology, 250 East Superior Street, Chicago, IL 60611 United States
 Journal of Heart Valve Disease (J. HEART VALVE DIS.) (United Kingdom)
 2001, 10/6 (827-831)
 CODEN: JHVDE ISSN: 0966-8519
 DOCUMENT TYPE: Journal ; Article
 LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH
 NUMBER OF REFERENCES: 17

...proliferative effects of serotonin (10SUP-8to 10SUP-6M) on cultured
 porcine aortic valve cells via a [SUP3H]thymidine assay were determined in
 vitro. Serotonin receptor **antagonist** studies in culture were also
 performed using methiotepin, a 5HTSUB1b **antagonist** , and ketanserin, a
 5HTSUB2 receptor **antagonist** , to determine the mechanism of serotonin
 action. The ex-vivo **proliferation** level in human carcinoid (n = 26) and
 normal valves (n = 10) was compared using proliferating cell nuclear
 antigen (PCNA) staining, a marker for **proliferation** . Identification and
 localization of specific 5HT receptor was assessed by immunostaining for
 serotonin receptors in the valves. Results: Serotonin increased valvular
proliferation in vitro in a dose-dependent manner (10-fold increase) (p
 <0.001), and this mitogenic effect was inhibited by methiotepin but not
 ketanserin. In human carcinoid heart valves the level of **proliferation**
 was 35-fold higher than in normal human valves (p <0.001). 5HTSUB1b
 receptors were found only in the carcinoid valves, and not in the normal
 valves. Conclusion: Serotonin is a powerful mitogen for valvular
 subendocardial cells. The mitogenic effect is at least partly mediated via
 5HTSUB1b receptors. Subendothelial cell **proliferation** is significantly
 elevated in human carcinoid valves in vivo. The data suggest a mechanism
 whereby serotonin may contribute to valvular **proliferation** in carcinoid
 heart disease.

6/3,K/9 (Item 4 from file: 73)
 DIALOG(R)File 73:EMBASE
 (c) 2004 Elsevier Science B.V. All rts. reserv.

01495127 EMBASE No: 1979216176
Some recent advances in cardiac pathology
 Billingham M.E.
 Dept. Pathol., Stanford Univ. Sch. Med., Stanford, Calif. United States
 Human Pathology (HUM. PATHOL.) (United States) 1979, 10/4 (367-386)
 CODEN: HPCQA
 DOCUMENT TYPE: Journal
 LANGUAGE: ENGLISH

This article has reviewed some recent advances in human cardiac
 pathology. The areas selected were cardiac transplant pathology, the
 lesions of **drug** cardiotoxicity, and the morphology of tissue **heart**
valve replacements. The **proliferation** of work in the first two areas is
 largely the result of the successful introduction of a new procedure,
 endomyocardial biopsy, which has made it...
 ?

Set	Items	Description
S1	269	(HEART (W) VALVE) (W) (DEGENERATION OR THROMBOSIS OR CALCI- FICATION)
S2	13	S1 (S) (INHIBITOR OR DRUG)
S3	7	RD (unique items)
S4	0	S1 (S) (INDUCED (W) PROLIFERATION)
S5	12	(INHIBITOR OR DRUG OR ANTAGONIST) (S) (PROLIFERATION AND (- HEART (W) VALVE))
S6	9	RD (unique items)
?		

S (SCREENING OR IDENTIFYING) (S) (INHIBITORS OR DRUGS OR ANTAGONISTS)
546440 SCREENING
139087 IDENTIFYING
834708 INHIBITORS
954099 DRUGS
563388 ANTAGONISTS
S7 28060 (SCREENING OR IDENTIFYING) (S) (INHIBITORS OR DRUGS OR
ANTAGONISTS)

?

S S1 AND S7

269 S1
28060 S7
S8 1 S1 AND S7

?

T S8/3,K/ALL

8/3,K/1 (Item 1 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2004 BIOSIS. All rts. reserv.

0014679298 BIOSIS NO.: 200400060055

Bioprosthetic heart valves

AUTHOR: Rajamannan Nalini M (Reprint)
AUTHOR ADDRESS: Rochester, MN, USA**USA
JOURNAL: Official Gazette of the United States Patent and Trademark Office
Patents 1277 (2): Dec. 9, 2003 2003
MEDIUM: e-file
PATENT NUMBER: US 6660260 PATENT DATE GRANTED: December 09, 2003 20031209
PATENT CLASSIFICATION: 424-9321 PATENT ASSIGNEE: Mayo Foundation for
Medical Education and Research PATENT COUNTRY: USA
ISSN: 0098-1133 (ISSN print)
DOCUMENT TYPE: Patent
RECORD TYPE: Abstract
LANGUAGE: English

...ABSTRACT: heart valve cells and heart valve cusps as well as methods for
making heart valves. The invention also provides methods and materials
for (1) slowing **heart valve degeneration**, thrombosis, and
calcification, (2) treating carcinoid heart disease, (3) **identifying**
inhibitors of heart valve degeneration, thrombosis, and
calcification, and (4) determining the safety of **drugs**.

DESCRIPTORS:

...DISEASES: **heart valve degeneration** --

?

Set	Items	Description
S1	269	(HEART (W) VALVE) (W) (DEGENERATION OR THROMBOSIS OR CALCI- FICATION)
S2	13	S1 (S) (INHIBITOR OR DRUG)
S3	7	RD (unique items)
S4	0	S1 (S) (INDUCED (W) PROLIFERATION)
S5	12	(INHIBITOR OR DRUG OR ANTAGONIST) (S) (PROLIFERATION AND (- HEART (W) VALVE))
S6	9	RD (unique items)
S7	28060	(SCREENING OR IDENTIFYING) (S) (INHIBITORS OR DRUGS OR ANT- AGONISTS)
S8	1	S1 AND S7
?		
S (HEART (W) VALVE) (S) (PROLIFERATION)		
	1845387	HEART
	204442	VALVE
	522377	PROLIFERATION
S9	56	(HEART (W) VALVE) (S) (PROLIFERATION)
?		
S S7 AND S9		

28060 S7
 56 S9
 S10 0 S7 AND S9
 ?
 S S9 AND (INHIBITOR? OR ANTAGONIST? OR DRUG?)
 Processing
 56 S9
 1935976 INHIBITOR?
 897063 ANTAGONIST?
 8640436 DRUG?
 S11 14 S9 AND (INHIBITOR? OR ANTAGONIST? OR DRUG?)
 ?
 RD
 ...completed examining records
 S12 8 RD (unique items)
 ?
 T S12/3,K/ALL

12/3,K/1 (Item 1 from file: 155)
 DIALOG(R)File 155:MEDLINE(R)
 (c) format only 2004 The Dialog Corp. All rts. reserv.

16932921 PMID: 15212624
Sarpogrelate: cardiovascular and renal clinical potential.
 Doggrell Sheila A
 Doggrell Biomedical Communications, 47 Caronia Crescent, Lynfield,
 Auckland, New Zealand. s.doggrell@xtra.co.nz
 Expert opinion on investigational drugs (England) Jul 2004, 13 (7)
 p865-74, ISSN 1744-7658 Journal Code: 9434197
 Document type: Journal Article
 Languages: ENGLISH
 Main Citation Owner: NLM
 Record type: In Process

Sarpogrelate is a selective 5-hydroxytryptamine receptor subtype 2A (5-HT_{2A}) **antagonist**. It is metabolised to racemic M-1 and both enantiomers of M-1 are also **antagonists** of 5-HT_{2A} receptors. Sarpogrelate inhibits responses to 5-HT mediated by 5-HT_{2A} receptors such as platelet aggregation, vasoconstriction and vascular smooth muscle proliferation...

... disease, myocardial infarction, diabetes and kidney disease. Small clinical trials indicate that sarpogrelate may be beneficial in the treatment of coronary artery disease, angina, restenosis, **heart valve** prostheses surgery, diabetes mellitus, Raynaud's phenomenon, systemic sclerosis and Buerger's disease. Larger, randomised, double-blind, placebo-controlled clinical trials of sarpogrelate in intermittent...

12/3,K/2 (Item 2 from file: 155)
 DIALOG(R)File 155:MEDLINE(R)
 (c) format only 2004 The Dialog Corp. All rts. reserv.

14439580 PMID: 10433819
Diminished matrix metalloproteinase 2 (MMP-2) in ectomesenchyme-derived tissues of the Patch mutant mouse: regulation of MMP-2 by PDGF and effects on mesenchymal cell migration.
 Robbins J R; McGuire P G; Wehrle-Haller B; Rogers S L
 Department of Cell Biology and Physiology, University of New Mexico
 School of Medicine, 149 Basic Medical Sciences Building, Albuquerque, New Mexico, 87131, USA.
 Developmental biology (UNITED STATES) Aug 15 1999, 212 (2) p255-63,
 ISSN 0012-1606 Journal Code: 0372762
 Contract/Grant No.: T32HL07736; HL; NHLBI
 Document type: Journal Article
 Languages: ENGLISH

Main Citation Owner: NLM

Record type: Completed

... receptor. Homozygous (Ph/Ph) embryos exhibit multiple connective tissue defects including cleft face (involving the first branchial arch and frontonasal processes), incomplete heart septation, and **heart valve** abnormalities before they die in utero. Analyses of the cell biology underlying the defects in Ph/Ph embryos have revealed a deficit in a matrix ...

...significantly less. In addition, the migratory ability of branchial arch cells from normal explants could be reduced in a similar manner using a specific **MMP inhibitor**. Although it is still unclear whether the MMP-2 reduction is a direct result of the absence of response of Ph/Ph cells to PDGF...

; Animals; Branchial Region--cytology--CY; Branchial Region--embryology--EM; Branchial Region--enzymology--EN; Face--embryology--EM; Gelatinase A; Gelatinases-- **antagonists and inhibitors** --AI; Heart--embryology--EM; Mesoderm--enzymology--EN; Metalloendopeptidases-- **antagonists and inhibitors** --AI; Mice; Mice, Mutant Strains; Morphogenesis; Myocardium--enzymology--EN; Skull--embryology--EM; Tissue Culture

12/3,K/3 (Item 3 from file: 155)

DIALOG(R) File 155:MEDLINE(R)

(c) format only 2004 The Dialog Corp. All rts. reserv.

13118099 PMID: 8784007

Impact of glutaraldehyde on calcification of pericardial bioprosthetic heart valve material.

Grabewoger M; Sider J; Fitzal F; Zelenka C; Windberger U; Grimm M; Moritz A; Bock P; Wolner E

Department of Cardio-Thoracic Surgery, University of Vienna, Austria.

Annals of thoracic surgery (UNITED STATES) Sep 1996, 62 (3) p772-7, ISSN 0003-4975 Journal Code: 15030100R

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: Completed

... by dye-mediated photooxidation showed no calcification after 63 days of subcutaneous implantation (1.0 +/- 0.4 mg Ca²⁺/g dry weight). Regular endothelial cell **proliferation** was observed on photooxidized and L-glutamic acid-treated tissue, whereas conventionally treated tissue caused endothelial cell death. **CONCLUSIONS:** This study underlines the detrimental role of glutaraldehyde in the calcification process of bioprosthetic **heart valve** materials and emphasizes alternative preservation methods that reduce or avoid the use of glutaraldehyde.

Descriptors: Bioprosthesis; *Calcinosis--pathology--PA; *Glutaral--pharmacology--PD; *Heart Valve Prosthesis; *Pericardium-- **drug effects** --DE

12/3,K/4 (Item 4 from file: 155)

DIALOG(R) File 155:MEDLINE(R)

(c) format only 2004 The Dialog Corp. All rts. reserv.

11208023 PMID: 11245774

The genetics and physiology of polycystic kidney disease.

Calvet J P; Grantham J J

Department of Biochemistry, Kidney Institute, University of Kansas Medical Center, Kansas City, KS, USA. jcalvet@kumc.edu

Seminars in nephrology (United States) Mar 2001, 21 (2) p107-23, ISSN 0270-9295 Journal Code: 8110298

Document type: Journal Article; Review; Review Literature

Languages: ENGLISH
Main Citation Owner: NLM
Record type: Completed

... 1 transcription factor. In addition, polycystin-2 may function in mediating calcium flux. The pathogenesis of cyst formation is currently thought to involve increased cell **proliferation**, fluid accumulation, and basement membrane remodeling. It now appears that cyclic adenosine monophosphate (cAMP) metabolism is a central component of cyst formation, stimulating apical chloride...

... cyst fluid. Recent evidence has shown that ADPKD cells also have an altered responsiveness to cyclic AMP. In contrast to normal kidney cells whose cell **proliferation** is inhibited by cyclic AMP, ADPKD cells are stimulated to proliferate. Thus, it is likely that an alteration in polycystin function transforms the normal cellular phenotype to one that responds to elevated cyclic AMP by an increased rate of cell **proliferation** and that the enlarging cyst expands by an increased rate of cyclic AMP-driven fluid secretion. Cyclic AMP and growth factors, including epidermal growth factor...

... effects to accelerate the enlargement of ADPKD cysts, and thereby to contribute to the progression of the disease. This knowledge should facilitate the discovery of **inhibitors** of signal transduction cascades that can be used in the treatment of ADPKD. Copyright 2001 by W.B. Saunders Company

12/3,K/5 (Item 5 from file: 155)
DIALOG(R) File 155:MEDLINE(R)
(c) format only 2004 The Dialog Corp. All rts. reserv.

09132515 PMID: 1728078

Glutaraldehyde affects biocompatibility of bioprosthetic heart valves.

Grimm M; Eybl E; Grabenwoger M; Spreitzer H; Jager W; Grimm G; Bock P; Muller M M; Wolner E

Second Department of Surgery, University of Vienna, Austria.

Surgery (UNITED STATES) Jan 1992, 111 (1) p74-8, ISSN 0039-6060

Journal Code: 0417347

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: Completed

... washing solutions was found by high performance liquid chromatography (up to 1.8 ppm of glutaraldehyde per gram of dry tissue). In vitro endothelial cell **proliferation** rate was impaired dose-dependently in the presence of increasing glutaraldehyde concentrations of the cultivation medium ($r = 0.9$; p less than 0.05). Cultivation...

; Animals; Cattle; Cell Division-- **drug** effects--DE; Cells, Cultured; Endothelium, Vascular--cytology--CY; Glutaral--analysis--AN; Materials Testing

12/3,K/6 (Item 1 from file: 73)
DIALOG(R) File 73:EMBASE
(c) 2004 Elsevier Science B.V. All rts. reserv.

12788379 EMBASE No: 2004382559

Heart valve development: Endothelial cell signaling and differentiation

Armstrong E.J.; Bischoff J.

Dr. J. Bischoff, Vascular Biology Program, Children's Hospital Boston, 300 Longwood Ave, Boston, MA 02115 United States

AUTHOR EMAIL: joyce.bischoff@childrens.harvard.edu

Circulation Research (CIRC. RES.) (United States) 03 SEP 2004, 95/5

(459-470)

CODEN: CIRUA ISSN: 0009-7330

DOCUMENT TYPE: Journal ; Review

LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

NUMBER OF REFERENCES: 99

...beta-catenin, BMP/TGF-beta, ErbB, and NF1/Ras. Based on the interactions among and relative timing of these pathways, a signaling network model for **heart valve** development is proposed.

DRUG DESCRIPTORS:

...epidermal growth factor receptor 2--endogenous compound--ec; epidermal growth factor receptor 3--endogenous compound--ec; epidermal growth factor receptor 4--endogenous compound--ec; unclassified **drug**

12/3,K/7 (Item 2 from file: 73)

DIALOG(R)File 73:EMBASE

(c) 2004 Elsevier Science B.V. All rts. reserv.

05146863 EMBASE No: 1992287096

Endothelial cell lining of bioprosthetic heart valve materials

Eybl E.; Grimm M.; Grabenwoger M.; Bock P.; Muller M.M.; Wolner E.

Second Department of Surgery, Zentrallabor B 800, University of Vienna,

Spitalgasse 23,A-1090 Vienna Austria

Journal of Thoracic and Cardiovascular Surgery (J. THORAC. CARDIOVASC. SURG.) (United States) 1992, 104/3 (763-769)

CODEN: JTCSA ISSN: 0022-5223

DOCUMENT TYPE: Journal; Article

LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

...of antithrombogenic potency of the seeded cells on L-glutamic acid-treated valve material was proved by regular release of prostacyclin. We conclude that bioprosthetic **heart valve** materials can be lined with endothelial cells if toxic glutaraldehyde released from the bioprostheses is eliminated.

DRUG DESCRIPTORS:

collagen; fibronectin; glutamic acid; glutaraldehyde-- **drug** toxicity--to; prostacyclin--endogenous compound--ec

12/3,K/8 (Item 3 from file: 73)

DIALOG(R)File 73:EMBASE

(c) 2004 Elsevier Science B.V. All rts. reserv.

01495127 EMBASE No: 1979216176

Some recent advances in cardiac pathology

Billingham M.E.

Dept. Pathol., Stanford Univ. Sch. Med., Stanford, Calif. United States

Human Pathology (HUM. PATHOL.) (United States) 1979, 10/4 (367-386)

CODEN: HPCQA

DOCUMENT TYPE: Journal

LANGUAGE: ENGLISH

This article has reviewed some recent advances in human cardiac pathology. The areas selected were cardiac transplant pathology, the lesions of **drug** cardiotoxicity, and the morphology of tissue **heart valve** replacements. The **proliferation** of work in the first two areas is largely the result of the successful introduction of a new procedure, endomyocardial biopsy, which has made it...

DRUG DESCRIPTORS:

* **drug**

MEDICAL DESCRIPTORS:

electron microscopy; histology; immunology; heart; adverse **drug** reaction; review

?

Set	Items	Description
S1	269	(HEART (W) VALVE) (W) (DEGENERATION OR THROMBOSIS OR CALCIFICATION)
S2	13	S1 (S) (INHIBITOR OR DRUG)
S3	7	RD (unique items)
S4	0	S1 (S) (INDUCED (W) PROLIFERATION)
S5	12	(INHIBITOR OR DRUG OR ANTAGONIST) (S) (PROLIFERATION AND (-HEART (W) VALVE))
S6	9	RD (unique items)
S7	28060	(SCREENING OR IDENTIFYING) (S) (INHIBITORS OR DRUGS OR ANTAGONISTS)
S8	1	S1 AND S7
S9	56	(HEART (W) VALVE) (S) (PROLIFERATION)
S10	0	S7 AND S9
S11	14	S9 AND (INHIBITOR? OR ANTAGONIST? OR DRUG?)
S12	8	RD (unique items)
?		
S S7 AND (PRAVASTATIN OR ATORVASTATIN OR SIMVASTATIN OR LOVSTATIN OR PINDOLOL OR MET		
	28060	S7
	10542	PRAVASTATIN
	6824	ATORVASTATIN
	13403	SIMVASTATIN
	7	LOVSTATIN
	16525	PINDOLOL
	0	METHTHIOTEPIN
	25629	METOPROLOL
	0	PALDOLOL
S13	277	S7 AND (PRAVASTATIN OR ATORVASTATIN OR SIMVASTATIN OR LOVSTATIN OR PINDOLOL OR METHTHIOTEPIN OR METOPROLOL OR PALDOLOL)
?		
S S1 AND S13		
	269	S1
	277	S13
S14	0	S1 AND S13
?		
S S13 AND (HEART (W) VALVE)		
	277	S13
	1845387	HEART
	204442	VALVE
	50434	HEART(W) VALVE
S15	0	S13 AND (HEART (W) VALVE)
?		
S (INHIBITED OR REDUCED) (S) (PROLIFERATION AND (HEART (W) VALVES))		
	912838	INHIBITED
	1711980	REDUCED
	522377	PROLIFERATION
	1845387	HEART
	41098	VALVES
	9808	HEART(W) VALVES
S16	18	(INHIBITED OR REDUCED) (S) (PROLIFERATION AND (HEART (W) VALVES))
?		
S S13 AND S16		
	277	S13
	18	S16
S17	0	S13 AND S16
?		
RD S18		
>>>Set 18 has not yet been created.		
?		
RD S16		
...completed examining records		
S18	8	RD S16 (unique items)

?
T S18/3,K/ALL

18/3,K/1 (Item 1 from file: 155)
DIALOG(R) File 155:MEDLINE(R)
(c) format only 2004 The Dialog Corp. All rts. reserv.

14290451 PMID: 10194805

Bisdiamine inhibits extracellular matrix formation and cell proliferation of atrioventricular mesenchyme from developing chick heart valves.

Choy M; Oltjen S L; Moon A J; Armstrong M T; Armstrong P B
Division of Pediatric Cardiology, University of California Davis Medical Center, Sacramento 95817, USA. mchoy@ucdavis.edu
Teratology (UNITED STATES) Mar 1999, 59 (3) p148-55, ISSN 0040-3709
Journal Code: 0153257

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: Completed

... on mesenchymal cells grown in aggregate culture isolated from the developing atrioventricular valves of the stage-36 chick embryo. Fibronectin extracellular matrix formation and cell **proliferation** in the aggregates were assessed in various media. Chick serum stimulated the cells to produce an extracellular matrix and to divide, and the inclusion of bisdiamine **inhibited** both responses. If we isolated an extracellular matrix from a monolayer of mesenchymal cells and added the sonicated matrix to the medium containing serum and...

... attach to an intact extracellular matrix to begin cell division. Thus, we suggest that bisdiamine inhibits the normal formation of the extracellular matrix, leading to **reduced** cell **proliferation**, but it does not affect matrix-cell interaction. The lack of cushion growth in situ may be the cause of AVSD or TA.

18/3,K/2 (Item 2 from file: 155)
DIALOG(R) File 155:MEDLINE(R)
(c) format only 2004 The Dialog Corp. All rts. reserv.

14210123 PMID: 9930452

Effect of antibiotic pretreatment on immunogenicity of human heart valves and component cells.

Johnson D L; Sloan C; O'Halloran A; Yacoub M H
Department of Cardiothoracic Surgery, National Heart and Lung Institute, Imperial College at Harefield Hospital, Heart Science Centre, Middlesex, United Kingdom.

Annals of thoracic surgery (UNITED STATES) Dec 1998, 66 (6 Suppl) pS221-4, ISSN 0003-4975 Journal Code: 15030100R

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: Completed

... low-dose antibiotics, peripheral blood mononuclear cells and human allogenic T cells were cocultured with antibiotic-treated valve discs, cultured valve endothelial cells, and fibroblasts. **Proliferation** was measured by uptake of thymidine labeled with hydrogen 3. RESULTS: Untreated tissue pieces stimulate peripheral blood mononuclear cells (4,080+/-980 cpm) at day...

... study shows that valve tissue is immunogenic and this immunogenicity is mediated mainly by endothelial cells. However, the immunostimulatory potential of the valve can be **reduced** by incubating the solution in an antibiotic cocktail.

18/3,K/3 (Item 3 from file: 155)

DIALOG(R) File 155:MEDLINE(R)

(c) format only 2004 The Dialog Corp. All rts. reserv.

13165284 PMID: 8834727

In vitro endothelialization of bioprosthetic heart valves.

Fischlein T; Fasol R

Department of Cardiac Surgery Grosshadern Medical Center, University of Munich, Germany.

Journal of heart valve disease (ENGLAND) Jan 1996, 5 (1) p58-65,
ISSN 0966-8519 Journal Code: 9312096

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: Completed

... to conventional bioprosthetic heart valves, glutaraldehyde preserved porcine aortic valve leaflets were precoated with fibronectin-heparin and acidic fibroblast growth factor (aFGF) to enhance cell **proliferation**. Furthermore, different methods of storage and preservation (1.0% benzoic acid, 1.0% sorbic acid, 0.05% and 0.5% dialdehyde starch) were compared to ...

...aFGF protein and endothelial cells improved in vitro and in vivo results significantly. CONCLUSIONS: Our study shows that endothelial cell growth as well as significantly **reduced** in vivo degeneration and mineralization of valve leaflets may be feasible if bioprosthetic **heart valves** are processed according to alternative, non-toxic conservation procedures and are precoated with angiogenic growth factor protein.

18/3,K/4 (Item 4 from file: 155)

DIALOG(R) File 155:MEDLINE(R)

(c) format only 2004 The Dialog Corp. All rts. reserv.

13103742 PMID: 8725286

Fibroblast growth factor-2 stimulates embryonic cardiac mesenchymal cell proliferation.

Choy M; Oltjen S L; Otani Y S; Armstrong M T; Armstrong P B

Division of Pediatric Cardiology, University of California Davis Medical Center, Sacramento 95817, USA.

Developmental dynamics - an official publication of the American Association of Anatomists (UNITED STATES) Jun 1996, 206 (2) p193-200,
ISSN 1058-8388 Journal Code: 9201927

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: Completed

The **proliferation** response of stage 36 chick atrioventricular valve mesenchymal cells to fibroblast growth factor-2 (FGF-2) was studied in the tissue-like environment of three...

... inclusion of Arg-Gly-Asp-containing peptides, which compete with fibronectin for binding to the cell surface alpha 5 beta 1 integrin receptors, abolished the **proliferation** effects of FGF-2. Inhibition of sulfation of cell surface glycosaminoglycans by treatment with sodium chlorate significantly **reduced** both the formation of the fibronectin matrix and cell **proliferation** in response to FGF-2, suggesting an involvement of the low-affinity sulfated glycosaminoglycan FGF receptor system. Thus, the FGF-stimulated growth of embryonic atrioventricular...

18/3,K/5 (Item 5 from file: 155)

DIALOG(R) File 155:MEDLINE(R)

(c) format only 2004 The Dialog Corp. All rts. reserv.

12387819 PMID: 12773386

Defective valvulogenesis in HB-EGF and TACE-null mice is associated with aberrant BMP signaling.

Jackson Leslie F; Qiu Ting Hu; Sunnarborg Susan W; Chang Aileen; Zhang Chunlian; Patterson Cam; Lee David C

Department of Biochemistry & Biophysics, UNC Lineberger Comprehensive Cancer Center, University of North Carolina School of Medicine, Chapel Hill, NC 27599, USA.

EMBO journal (England) Jun 2 2003, 22 (11) p2704-16, ISSN 0261-4189
Journal Code: 8208664

Contract/Grant No.: AG021096; AG; NIA; CA43793; CA; NCI; CA61896; CA; NCI; CA85410; CA; NCI; HL65619; HL; NHLBI

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: Completed

... double null HB-EGF(-/-)/BTC(-/-) mice was further reduced, apparently due to accelerated heart failure. HB-EGF(-/-) newborns had enlarged and malformed semilunar and atrioventricular heart valves, and hypoplastic, poorly differentiated lungs. Defective cardiac valvulogenesis was the result of abnormal mesenchymal cell proliferation during remodeling, and was associated with dramatic increases in activated Smad1/5/8. Consistent with the phenotype, HB-EGF transcripts were localized to endocardial cells ...

18/3,K/6 (Item 6 from file: 155)

DIALOG(R) File 155:MEDLINE(R)

(c) format only 2004 The Dialog Corp. All rts. reserv.

11585869 PMID: 11767194

Cell proliferation in carcinoid valve disease: a mechanism for serotonin effects.

Rajamannan N M; Caplice N; Anthikad F; Sebo T J; Orszulak T A; Edwards W D; Tajik J; Schwartz R S

Division of Cardiovascular Diseases and Internal Medicine, Mayo Clinic and Mayo Foundation, Rochester, Minnesota, USA.

Journal of heart valve disease (England) Nov 2001, 10 (6) p827-31, ISSN 0966-8519 Journal Code: 9312096

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: Completed

...culture were also performed using methiotepin, a 5HT1b antagonist, and ketanserin, a 5HT2 receptor antagonist, to determine the mechanism of serotonin action. The ex-vivo proliferation level in human carcinoid (n = 26) and normal valves (n = 10) was compared using proliferating cell nuclear antigen (PCNA) staining, a marker for proliferation. Identification and localization of specific 5HT receptor was assessed by immunostaining for serotonin receptors in the valves. RESULTS: Serotonin increased valvular proliferation in vitro in a dose-dependent manner (10-fold increase) (p <0.001), and this mitogenic effect was inhibited by methiotepin but not ketanserin. In human carcinoid heart valves the level of proliferation was 35-fold higher than in normal human valves (p <0.001). 5HT1b receptors were found only in the carcinoid valves, and not in the normal valves. CONCLUSION: Serotonin is a powerful mitogen for valvular subendocardial cells. The mitogenic effect is at least partly mediated via 5HT1b receptors. Subendothelial cell proliferation is significantly elevated in human carcinoid valves in vivo. The data suggest a mechanism whereby serotonin may contribute to valvular proliferation in carcinoid heart disease.

18/3,K/7 (Item 7 from file: 155)

DIALOG(R) File 155:MEDLINE(R)

(c) format only 2004 The Dialog Corp. All rts. reserv.

10289041 PMID: 7986560

Integrity and viability of homograft valves.

Fischlein T; Schutz A; Uhlig A; Frey R; Krupa W; Babic R; Thiery J; Reichart B

Department of Cardiac Surgery, University of Munich, Germany.

European journal of cardio-thoracic surgery - official journal of the European Association for Cardio-thoracic Surgery (GERMANY) 1994, 8 (8) p425-30, ISSN 1010-7940 Journal Code: 8804069

Comment in Eur J Cardiothorac Surg. 1995;9(2) 113; Comment in PMID 7748572

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: Completed

... 3 days beforehand. Morphological observations were made using light and electron microscopy and, in order to characterize the endothelial cell viability, a non-radioactive cell **proliferation** assay was used. The PGI2 secretion of the remaining endothelium was defined as the 6-keto-prostaglandin F1 alpha metabolite by an enzyme immunoassay. Observations...

... of HBD homografts was maintained was confirmed by proven PGI2 secretion (6150 +/- 1200 pg/3 ml M199 after cryopreservation), whereas specimens from NHBD showed a **reduced** (1950 +/- 730 pg/3 ml M199) and, after cryopreservation, almost no release (P < 0.0001). (ABSTRACT TRUNCATED AT 250 WORDS)

18/3,K/8 (Item 8 from file: 155)

DIALOG(R) File 155:MEDLINE(R)

(c) format only 2004 The Dialog Corp. All rts. reserv.

07260406 PMID: 3490326

Porcine heart valves produce a protein that induces cell-mediated connective tissue degradation: II. Biochemical properties of the partially purified protein.

Decker R S; Henney A M; Dingle J T

Circulation research (UNITED STATES) Sep 1986, 59 (3) p329-41, ISSN 0009-7330 Journal Code: 0047103

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: Completed

...release of glycosaminoglycans from cultured cartilage and mitral valve and provoked porcine valves to degrade their own collagen extracellular matrix. The release of hydroxyproline was **inhibited** by corticosteroids, whereas proteoglycan breakdown was not. Partially pure preparations of CCF and synovial catabolin stimulated murine thymocyte **proliferation**; moreover, that activity was almost totally abolished by an antibody raised against pure porcine interleukin-1. These observations suggest that CCF may represent a catabolic...

?

Set	Items	Description
S1	269	(HEART (W) VALVE) (W) (DEGENERATION OR THROMBOSIS OR CALCIFICATION)
S2	13	S1 (S) (INHIBITOR OR DRUG)
S3	7	RD (unique items)

S4 0 S1 (S) (INDUCED (W) PROLIFERATION)
 S5 12 (INHIBITOR OR DRUG OR ANTAGONIST) (S) (PROLIFERATION AND (-
 HEART (W) VALVE))
 S6 9 RD (unique items)
 S7 28060 (SCREENING OR IDENTIFYING) (S) (INHIBITORS OR DRUGS OR ANT-
 AGONISTS)
 S8 1 S1 AND S7
 S9 56 (HEART (W) VALVE) (S) (PROLIFERATION)
 S10 0 S7 AND S9
 S11 14 S9 AND (INHIBITOR? OR ANTAGONIST? OR DRUG?)
 S12 8 RD (unique items)
 S13 277 S7 AND (PRAVASTATIN OR ATORVASTATIN OR SIMVASTATIN OR LOVS-
 TATIN OR PINDOLOL OR METHTHIOTEPIN OR METOPROLOL OR PALDOLOL)
 S14 0 S1 AND S13
 S15 0 S13 AND (HEART (W) VALVE)
 S16 18 (INHIBITED OR REDUCED) (S) (PROLIFERATION AND (HEART (W) V-
 ALVES))
 S17 0 S13 AND S16
 S18 8 RD S16 (unique items)
 ?
 COST

26oct04 15:06:34 User259876 Session D684.2

\$6.31 1.971 DialUnits File155
 \$4.62 22 Type(s) in Format 3
 \$4.62 22 Types
 \$10.93 Estimated cost File155
 \$7.54 1.347 DialUnits File5
 \$7.00 4 Type(s) in Format 3
 \$7.00 4 Types
 \$14.54 Estimated cost File5
 \$27.62 2.819 DialUnits File73
 \$18.90 7 Type(s) in Format 3
 \$18.90 7 Types
 \$46.52 Estimated cost File73
 OneSearch, 3 files, 6.137 DialUnits FileOS
 \$8.00 INTERNET
 \$79.99 Estimated cost this search
 \$80.77 Estimated total session cost 6.345 DialUnits

?

Return to logon page!